Core Insights - Rani Therapeutics is participating in the Evercore Healthcare Conference on December 3, 2025, with CEO Talat Imran and CFO Svai Sanford presenting [1] - The company focuses on oral delivery of biologics and drugs, aiming to replace traditional injection methods with its proprietary RaniPill capsule technology [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company dedicated to advancing technologies for orally administered biologics and drugs [2] - The RaniPill capsule is a novel, proprietary, and patented platform technology designed to facilitate oral dosing instead of subcutaneous or intravenous methods [2] - The company has successfully conducted multiple preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill capsule technology [2]

Core Insights - Rani Therapeutics has entered into a research agreement with Chugai Pharmaceutical to evaluate the feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets [1][2] - The RaniPill delivery system has demonstrated comparable bioavailability to subcutaneous delivery for the studied molecules [1] - Rani Therapeutics has evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials with the RaniPill capsule, showcasing its broad applicability across various biologics [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company focused on developing technologies for orally administered biologics and drugs, specifically through its proprietary RaniPill capsule [3] - The RaniPill capsule aims to replace subcutaneous injections or intravenous infusions with oral dosing, having successfully conducted several preclinical and clinical studies to evaluate its safety, tolerability, and bioavailability [3] Chugai Pharmaceutical Overview - Chugai Pharmaceutical, headquartered in Tokyo, is a research-based pharmaceutical company known for its drug discovery capabilities, including proprietary antibody engineering technologies [4] - The company is committed to creating innovative pharmaceutical products to address unmet medical needs and is a significant member of the Roche Group while maintaining its management independence [4]